| Syeda M Sayeed, MD | |
|
1030 President Ave Rm 305a, Fall River, MA 02720-5929 | |
| (508) 235-6744 | |
| (888) 815-1696 |
| Full Name | Syeda M Sayeed |
|---|---|
| Gender | Female |
| Speciality | Rheumatology |
| Experience | 19 Years |
| Location | 1030 President Ave Rm 305a, Fall River, Massachusetts |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1205034311 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RR0500X | Internal Medicine - Rheumatology | 273247 (Massachusetts) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Southcoast Hospitals Group | Fall river, MA | Hospital |
| Entity Name | Ocean State Rheumatology Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033714159 PECOS PAC ID: 9638585284 Enrollment ID: O20210308000753 |
News Archive
Sixteen million family members in the U.S. are caregivers for the more than 6 million people living with Alzheimer's Disease and Related Dementias (ADRD).
Researchers at Washington University School of Medicine in St. Louis have identified a chain reaction that triggers the regrowth of some damaged nerve cell branches, a discovery that one day may help improve treatments for nerve injuries that can cause loss of sensation or paralysis.
A new study by an international team led by Dana-Farber Cancer Institute scientists provides the first statistically-based guidelines for determining whether a stem cell transplant is appropriate for older patients with myelodysplastic syndromes - the most common blood disorders in people over 60 years of age, and frequently a precursor for leukemia.
Depression among youth is a growing public health concern, affecting one to two percent of elementary school-aged children and three to eight percent of adolescents.
Vertex Pharmaceuticals Incorporated today announced the initiation of a Phase 3b study called OPTIMIZE that will evaluate twice-daily (BID) dosing of a telaprevir-based combination regimen in people chronically infected with genotype 1 hepatitis C virus (HCV) who have not been treated previously. This is the first Phase 3 study to evaluate twice-daily dosing of a protease inhibitor for the treatment of hepatitis C. OPTIMIZE will not include a control arm of pegylated-interferon and ribavirin alone.
› Verified 3 days ago
| Entity Name | Ocean State Infusions |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568140192 PECOS PAC ID: 8820451099 Enrollment ID: O20230906001020 |
News Archive
Sixteen million family members in the U.S. are caregivers for the more than 6 million people living with Alzheimer's Disease and Related Dementias (ADRD).
Researchers at Washington University School of Medicine in St. Louis have identified a chain reaction that triggers the regrowth of some damaged nerve cell branches, a discovery that one day may help improve treatments for nerve injuries that can cause loss of sensation or paralysis.
A new study by an international team led by Dana-Farber Cancer Institute scientists provides the first statistically-based guidelines for determining whether a stem cell transplant is appropriate for older patients with myelodysplastic syndromes - the most common blood disorders in people over 60 years of age, and frequently a precursor for leukemia.
Depression among youth is a growing public health concern, affecting one to two percent of elementary school-aged children and three to eight percent of adolescents.
Vertex Pharmaceuticals Incorporated today announced the initiation of a Phase 3b study called OPTIMIZE that will evaluate twice-daily (BID) dosing of a telaprevir-based combination regimen in people chronically infected with genotype 1 hepatitis C virus (HCV) who have not been treated previously. This is the first Phase 3 study to evaluate twice-daily dosing of a protease inhibitor for the treatment of hepatitis C. OPTIMIZE will not include a control arm of pegylated-interferon and ribavirin alone.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Syeda M Sayeed, MD 1030 President Ave Rm 305a, Fall River, MA 02720-5929 Ph: (508) 235-6744 | Syeda M Sayeed, MD 1030 President Ave Rm 305a, Fall River, MA 02720-5929 Ph: (508) 235-6744 |
News Archive
Sixteen million family members in the U.S. are caregivers for the more than 6 million people living with Alzheimer's Disease and Related Dementias (ADRD).
Researchers at Washington University School of Medicine in St. Louis have identified a chain reaction that triggers the regrowth of some damaged nerve cell branches, a discovery that one day may help improve treatments for nerve injuries that can cause loss of sensation or paralysis.
A new study by an international team led by Dana-Farber Cancer Institute scientists provides the first statistically-based guidelines for determining whether a stem cell transplant is appropriate for older patients with myelodysplastic syndromes - the most common blood disorders in people over 60 years of age, and frequently a precursor for leukemia.
Depression among youth is a growing public health concern, affecting one to two percent of elementary school-aged children and three to eight percent of adolescents.
Vertex Pharmaceuticals Incorporated today announced the initiation of a Phase 3b study called OPTIMIZE that will evaluate twice-daily (BID) dosing of a telaprevir-based combination regimen in people chronically infected with genotype 1 hepatitis C virus (HCV) who have not been treated previously. This is the first Phase 3 study to evaluate twice-daily dosing of a protease inhibitor for the treatment of hepatitis C. OPTIMIZE will not include a control arm of pegylated-interferon and ribavirin alone.
› Verified 3 days ago
Stephen Zuehlke, M.D. Rheumatology Medicare: Medicare Enrolled Practice Location: 289 Pleasant St, Suite 301, Fall River, MA 02721 Phone: 508-679-9955 Fax: 508-679-1435 | |
Terence J Mcgovern, MD Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 1030 President Ave, Suite 210, Fall River, MA 02720 Phone: 508-973-1780 Fax: 508-973-0359 | |
Raju Singla, M.D. Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 289 Pleasant St, Fall River, MA 02721 Phone: 508-646-7730 Fax: 508-672-0885 | |
Ronald Bruce Goodspeed, M.D. Rheumatology Medicare: Not Enrolled in Medicare Practice Location: 363 Highland Ave, Fall River, MA 02720 Phone: 508-679-7013 | |
Linsey Philip, M.D. Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 277 Pleasant St, Suite 306, Fall River, MA 02721 Phone: 508-675-3232 Fax: 508-675-4942 | |
Dr. Tricia A Carty, MD Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 534 Prospect St, Fall River, MA 02720 Phone: 508-973-7766 Fax: 508-973-7753 | |
Dr. Nick Mucciardi, MD Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 1030 President Ave, Suite 210, Fall River, MA 02720 Phone: 508-973-1780 Fax: 508-973-0359 |